# FLRT2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- FLRT2 is a type I transmembrane protein encoded by a gene located at 14q31.3, characterized by 13 exons and a CpG island promoter susceptible to hypermethylation, leading to transcriptional silencing in various cancers.
- The FLRT2 protein possesses a modular extracellular domain comprising Leucine-Rich Repeats (LRRs) and a Fibronectin Type III (FN3) domain, facilitating cell adhesion and interaction with receptor tyrosine kinases like FGFR1, thereby modulating FGF signaling.
- FLRT2 plays critical roles in neurodevelopment, including cortical interneuron migration and synapse formation, and is essential for proper heart and craniofacial morphogenesis, with loss-of-function associated with microphthalmia and congenital heart defects.
- In cancer, FLRT2 functions as a tumor suppressor, frequently inactivated by promoter hypermethylation in colorectal, breast, and bladder cancers, where it can induce ferroptosis by regulating the cystine/glutamate antiporter system xc⁻.
- Therapeutic strategies for FLRT2-silenced cancers focus on reactivation via demethylating agents (e.g., 5-azacitidine) and histone deacetylase inhibitors, while in vascular graft engineering, FLRT2 silencing in endothelial cells enhances graft patency.
- Germline mutations in *FLRT2* are implicated in developmental disorders, and its epigenetic silencing via promoter hypermethylation is a primary mechanism of inactivation in tumorigenesis, making FLRT2 promoter methylation a potential biomarker.

---

## Executive Summary & Key Metadata

The Fibronectin Leucine-Rich Transmembrane protein 2 (FLRT2) gene encodes a type I transmembrane protein that operates at the interface of cell adhesion, cell migration, and receptor tyrosine kinase signaling. Initially identified as a member of a novel family of transmembrane leucine-rich repeat (LRR) proteins [1], FLRT2 has emerged as a critical regulator of developmental morphogenesis, particularly in the central nervous system, heart, and craniofacial structures [2, 3, 4, 5, 6]. Beyond its developmental roles, FLRT2 functions as a context-dependent tumor suppressor, frequently silenced by promoter hypermethylation in colorectal, breast, and bladder cancers [7, 8, 9]. The protein also modulates endothelial cell adhesion dynamics relevant to vascular graft engineering [10, 11, 12].

| Attribute | Detail |
| :--- | :--- |
| **HGNC Symbol** | FLRT2 |
| **UniProt Accession** | O43155 |
| **Representative PDB ID** | True (structural models available via homology; see Section 2) |
| **Chromosomal Locus** | 14q31.3 (GRCh38: chr14:85,500,000–85,650,000) |
| **Primary Molecular Function** | Cell adhesion molecule; modulator of FGF signaling; regulator of neuronal migration and synapse formation |
| **Disease & Pathology Associations** | Colorectal cancer, breast cancer, bladder cancer, congenital heart defects, microphthalmia, neurodevelopmental abnormalities |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *FLRT2* gene is located on the long arm of human chromosome 14 at cytogenetic band 14q31.3. The gene spans approximately 150 kilobases (kb) of genomic DNA on the minus strand. The precise coordinates in the GRCh38 assembly are chr14:85,500,000–85,650,000. The gene comprises 13 exons, with the translational start site located in exon 1 and the stop codon in exon 13. The intron-exon boundaries are conserved across mammals, reflecting strong purifying selection on the coding sequence.

The core promoter region is characterized by a CpG island spanning the first exon and extending into the first intron. This CpG island is a critical regulatory feature, as its methylation status directly correlates with transcriptional silencing in multiple cancer types [7, 9]. The promoter lacks a canonical TATA box but contains multiple GC-boxes that serve as binding sites for the transcription factor Sp1. Additionally, predicted binding sites for ETS-family transcription factors and AP-1 are present, suggesting responsiveness to growth factor signaling and stress pathways.

### 1.2 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project reveal several putative enhancer elements within the first and second introns of *FLRT2*. These regions are marked by H3K27ac and H3K4me1 histone modifications in human brain and heart tissues, consistent with the gene's prominent expression in these organs. A distal enhancer located approximately 50 kb upstream of the transcription start site has been shown to interact with the promoter via chromatin looping in neural progenitor cells. This long-range interaction is mediated by the CCCTC-binding factor (CTCF) and is dynamically regulated during neuronal differentiation.

### 1.3 Transcription Factor Binding and Regulatory Networks

The transcription factor SATB2, a global chromatin organizer, directly binds to the *FLRT2* locus and positively regulates its expression in the developing cerebral cortex [13]. SATB2-dependent regulation of *FLRT2* is essential for proper axonogenesis and synapse formation, as *FLRT2* is one of the downstream effectors mediating SATB2's effects on neuronal connectivity [13]. In the embryonic heart, the histone methyltransferase SETD2 regulates *FLRT2* expression through H3K36me3 deposition, linking epigenetic regulation to coronary vascular development [14]. Glucocorticoid receptor (GR; NR3C1) signaling also modulates *FLRT2* transcript levels in airway epithelial cells, suggesting a role in inflammatory responses [15].

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of *FLRT2* produces multiple transcript variants. The predominant full-length isoform encodes a 840-amino acid protein. A second major isoform, generated by the inclusion of an alternative exon 8, results in a protein with a modified juxtamembrane stalk region. This isoform exhibits differential glycosylation patterns and altered subcellular localization. A third, minor isoform lacks exon 11, which encodes a portion of the cytoplasmic tail; this variant is predicted to have impaired intracellular signaling capacity. The relative abundance of these isoforms is tissue-specific, with the full-length isoform dominating in the brain and heart, while the exon 8-inclusion isoform is more prevalent in the lung and kidney.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The FLRT2 protein is a type I transmembrane glycoprotein with a modular architecture. From the N-terminus to the C-terminus, the protein comprises the following domains:

1.  **Signal Peptide (aa 1–24):** Directs the nascent polypeptide to the endoplasmic reticulum for co-translational translocation.
2.  **Leucine-Rich Repeat (LRR) Domain (aa 25–330):** The largest extracellular domain, composed of 10 tandem LRRs. Each LRR adopts a β-strand–loop–α-helix conformation, and the repeats stack to form a curved, horseshoe-shaped solenoid structure. The concave face of this solenoid is the primary site for protein-protein interactions. The LRR domain is flanked by N-terminal (LRRNT) and C-terminal (LRRCT) cysteine-rich capping modules that stabilize the overall fold.
3.  **Fibronectin Type III (FN3) Domain (aa 340–450):** A single FN3 domain follows the LRR region. This domain adopts a β-sandwich fold composed of two antiparallel β-sheets. FN3 domains are canonical protein-protein interaction modules found in many adhesion molecules and receptor tyrosine kinases.
4.  **Juxtamembrane Region (aa 451–480):** A flexible, glycosylated linker region connecting the FN3 domain to the transmembrane helix.
5.  **Transmembrane Helix (aa 481–503):** A single hydrophobic α-helix that anchors the protein in the plasma membrane.
6.  **Cytoplasmic Tail (aa 504–840):** The intracellular domain is intrinsically disordered but contains several conserved motifs, including a PDZ-binding motif at the extreme C-terminus (ETSV) and multiple proline-rich regions that serve as docking sites for SH3-domain-containing proteins.

### 2.2 Structural Homology and 3D Models

While a high-resolution crystal structure of the full-length human FLRT2 protein has not yet been determined, the structures of homologous LRR-containing proteins and the isolated FN3 domain provide robust templates for homology modeling. The LRR domain of FLRT2 is predicted to share high structural similarity with the LRR domains of other FLRT family members and with the ectodomains of the Slit and Toll-like receptor families. The concave surface of the LRR solenoid is lined with conserved asparagine residues that form an extensive hydrogen-bonding network, characteristic of protein-binding interfaces.

The FN3 domain of FLRT2 is structurally similar to the FN3 domains found in fibronectin itself and in the receptor protein tyrosine phosphatase mu (RPTPμ). This domain is critical for mediating homophilic and heterophilic cell-cell adhesion.

### 2.3 Post-Translational Modifications

FLRT2 is heavily glycosylated. The LRR domain contains multiple N-linked glycosylation sites (Asn-X-Ser/Thr motifs), and glycosylation is essential for proper protein folding and cell-surface expression. The juxtamembrane region also contains O-linked glycosylation sites. The cytoplasmic tail is subject to phosphorylation, although the specific kinases and phosphatases that regulate this have not been fully characterized. Ubiquitination of lysine residues in the cytoplasmic tail can target FLRT2 for proteasomal degradation, providing a mechanism for rapid downregulation of cell-surface protein.

### 2.4 Interactive 3D Visualization

To explore the predicted three-dimensional structure of the FLRT2 protein, including the LRR solenoid and FN3 domain, use the interactive visualizer tool.

[Interactive 3D Protein Visualizer: Load FLRT2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O43155)

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Role in FGF Signaling Modulation

FLRT2 is a well-established modulator of Fibroblast Growth Factor (FGF) signaling. The protein physically interacts with Fibroblast Growth Factor Receptor 1 (FGFR1) and attenuates FGF-mediated signal transduction [2, 16]. This interaction is mediated by the extracellular LRR domain of FLRT2, which binds to the immunoglobulin-like domains of FGFR1. By sequestering FGFR1 or altering its conformation, FLRT2 reduces the receptor's affinity for its ligands and dampens downstream signaling cascades, including the RAS-MAPK and PI3K-AKT pathways.

This regulatory function is critical during development. In zebrafish, loss of *flrt2* leads to microphthalmia, a condition characterized by abnormally small eyes, due to dysregulated FGF signaling during optic vesicle development [2]. Similarly, in the developing somite, *Flrt2* expression in sclerotome cells is essential for proper FGF signaling gradients that pattern the vertebral column [2, 16].

### 3.2 Cell Adhesion and Migration

FLRT2 functions as a bona fide cell adhesion molecule. It mediates both homophilic (FLRT2-FLRT2) and heterophilic (FLRT2-FLRT3) cell-cell adhesion through its extracellular LRR domain [1, 6]. This adhesive function is crucial for the tangential migration of cortical interneurons. FLRT2 and FLRT3 cooperate to maintain the integrity of the migratory streams that guide interneurons from the ventral telencephalon to the cerebral cortex [6]. Disruption of this adhesive function leads to aberrant interneuron positioning and defective cortical circuitry.

In the retina, FLRT2 and its homolog FLRT3, along with Unc5 receptors, mediate neuronal subtype recognition, ensuring that specific neuronal subtypes synapse in the correct sublaminae of the inner plexiform layer [17]. This demonstrates a role for FLRT2 in precise synaptic connectivity.

### 3.3 Regulation of Endothelial Cell Adhesion

Recent studies have identified a novel role for FLRT2 in endothelial cell biology. Silencing *FLRT2* in endothelial cells enhances their retention on synthetic vascular graft materials under fluid shear stress conditions in vitro [10, 11, 12]. This finding has significant implications for tissue engineering, as poor endothelialization of small-diameter synthetic grafts is a major cause of graft failure. The mechanism appears to involve changes in the expression of integrins and other adhesion molecules, leading to increased cell-matrix adhesion and resistance to shear-induced detachment [12]. This positions FLRT2 as a potential target for improving the patency of synthetic vascular grafts.

### 3.4 Tumor Suppressor Activity and Ferroptosis

In multiple cancer types, FLRT2 acts as a tumor suppressor. Its expression is frequently lost due to promoter hypermethylation [7, 9]. In bladder cancer, FLRT2 suppresses tumor progression by inducing ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxidation [8]. The mechanism involves FLRT2-mediated regulation of the cystine/glutamate antiporter system xc⁻, leading to depletion of intracellular glutathione and subsequent accumulation of lipid reactive oxygen species (ROS). This triggers ferroptotic cell death and inhibits tumor growth [8].

In colorectal cancer, FLRT2 functions as a tumor suppressor, and its inactivation by promoter methylation is an early event in colorectal carcinogenesis [7]. Similarly, in breast cancer, FLRT2 shows tumor suppressor activity, and its expression is downregulated by hypermethylation [9, 18]. The prognostic significance of FLRT2 expression has been demonstrated in bladder cancer, where lower expression correlates with worse patient outcomes [19].

### 3.5 Protein-Protein Interaction Networks

FLRT2 participates in a complex network of protein-protein interactions. Key interactors include:

- **FGFR1:** Modulates FGF signaling [2, 16].
- **FLRT3:** Mediates heterophilic cell adhesion [6].
- **Unc5 receptors:** Mediate neuronal subtype recognition [17].
- **LPHN3 (Latrophilin 3):** A G-protein-coupled receptor that interacts with FLRT2 to regulate synapse formation.
- **Integrins:** Indirectly modulates cell-matrix adhesion [12].

```mermaid
sequenceDiagram
    participant EC as "Extracellular Space"
    participant M as "Plasma Membrane"
    participant IC as "Intracellular Space"
    participant F as "FGFR1"
    participant L as "FLRT2"
    participant U as "Unc5"
    participant I as "Integrins"
    Note over EC, IC: Cell Adhesion & Signaling
    L->>L: Homophilic Adhesion (FLRT2-FLRT2)
    L->>F: Heterophilic Interaction (FLRT2-FGFR1)
    F->>IC: Attenuated FGF Signaling (RAS-MAPK, PI3K-AKT)
    L->>U: Neuronal Subtype Recognition
    L->>I: Modulates Cell-Matrix Adhesion
    Note over IC: Tumor Suppression<br/>Ferroptosis Induction
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Developmental Disorders

Germline mutations in *FLRT2* are associated with a spectrum of developmental phenotypes. While comprehensive clinical databases list few definitive pathogenic variants, functional studies in animal models provide strong evidence for the consequences of FLRT2 loss-of-function.

- **Microphthalmia:** Loss of *flrt2* in zebrafish results in microphthalmia, indicating that FLRT2 is essential for proper eye development [2]. This suggests that human patients with biallelic loss-of-function mutations in *FLRT2* may present with similar ocular defects.
- **Congenital Heart Defects:** *Flrt2* is required in the epicardium for proper heart morphogenesis in mice [4]. Mutations affecting FLRT2 expression or function could contribute to congenital heart defects, particularly those involving coronary vascular development [14].
- **Craniofacial Abnormalities:** *Flrt2* and *Flrt3* have overlapping and non-overlapping expression patterns during craniofacial development [5]. Disruption of these genes may lead to craniofacial malformations.

### 4.2 Somatic Mutations and Epigenetic Silencing in Cancer

In cancer, the primary mechanism of FLRT2 inactivation is not necessarily mutation but rather epigenetic silencing via promoter hypermethylation. This has been demonstrated in:

- **Colorectal Cancer:** FLRT2 promoter methylation is a frequent event, leading to gene silencing and loss of tumor suppressor function [7].
- **Breast Cancer:** FLRT2 is hypermethylated and downregulated in breast cancer cell lines and primary tumors [9, 18].
- **Bladder Cancer:** FLRT2 expression is reduced in bladder cancer tissues, and this reduction is associated with poor prognosis [8, 19].

Somatic missense mutations in FLRT2 are less common but have been reported in various cancers. These mutations often occur in the extracellular LRR domain and may disrupt protein folding, cell-surface localization, or ligand binding. However, the functional consequences of most of these variants remain to be experimentally validated.

### 4.3 Clinical Differentials and Diagnostic Implications

The clinical presentation of FLRT2-related pathologies is highly variable, reflecting its pleiotropic functions. Differential diagnosis should consider:

- **For ocular phenotypes:** Other genes associated with microphthalmia, such as *SOX2*, *OTX2*, and *PAX6*.
- **For cardiac phenotypes:** Genes involved in congenital heart disease, including *NKX2-5*, *GATA4*, and *TBX5*.
- **For cancer:** Epigenetic silencing of other tumor suppressor genes, such as *CDKN2A* and *MLH1*.

The detection of FLRT2 promoter methylation in liquid biopsies (e.g., urine, plasma) holds promise as a non-invasive biomarker for cancer diagnosis and monitoring. Studies have explored DNA methylation biomarkers for renal cell carcinoma and small renal masses, and FLRT2 methylation could be incorporated into such panels [20, 21].

## 5. Host-Pathogen & Viral Interactions (If applicable)

### 5.1 Human Papillomavirus (HPV) and Bladder Cancer

There is emerging evidence linking HPV infection to the expression of FLRT2 in bladder cancer. A comprehensive prognostic model based on HPV-associated gene signatures identified FLRT2 as one of the key genes [22]. The model suggests that HPV infection may modulate the tumor immune microenvironment, and FLRT2 expression levels could influence the response to immunotherapy. However, the direct molecular interaction between HPV oncoproteins (E6/E7) and the FLRT2 protein has not been demonstrated.

### 5.2 Bornavirus-like Nucleoproteins

Endogenous Bornavirus-like nucleoprotein elements (EBLNs) are remnants of ancient viral infections integrated into the human genome. While the study of EBLN1 (a related gene) has shown effects on cell growth and apoptosis in oligodendroglia cells [23], a direct interaction with FLRT2 has not been reported. The relevance of this pathway to FLRT2 function remains speculative.

### 5.3 COVID-19 and Immune Status

Transcriptomic analyses of recovered COVID-19 patients have identified changes in the expression of various immune-related genes [24]. While FLRT2 was not a primary focus of these studies, its role in modulating immune responses and its expression in the respiratory epithelium suggest it could be part of the broader host response to viral infection. Further research is needed to clarify any direct involvement.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FLRT2 as a Therapeutic Target

Given its role as a tumor suppressor, the primary therapeutic strategy for cancers with FLRT2 silencing is **reactivation** of its expression, rather than inhibition. This can be achieved through:

- **Demethylating Agents:** Drugs such as 5-azacitidine and decitabine are nucleoside analogs that inhibit DNA methyltransferases (DNMTs). These agents can reverse promoter hypermethylation and restore FLRT2 expression in cancer cells [7, 9]. Clinical trials have established their efficacy in myelodysplastic syndromes and acute myeloid leukemia, and they are being investigated in solid tumors.
- **Histone Deacetylase (HDAC) Inhibitors:** These agents, such as vorinostat and romidepsin, alter chromatin structure and can synergize with demethylating agents to reactivate silenced genes.

### 6.2 Modulating FLRT2 for Vascular Graft Engineering

In the context of vascular graft engineering, **silencing** FLRT2 in endothelial cells is a potential strategy to enhance cell retention on graft materials [10, 11, 12]. This could be achieved ex vivo using:

- **Small Interfering RNA (siRNA):** Transfection of endothelial cells with FLRT2-specific siRNA prior to seeding on grafts.
- **Short Hairpin RNA (shRNA):** Stable knockdown using lentiviral or retroviral vectors.
- **CRISPR-Cas9 Gene Editing:** Permanent knockout of FLRT2 in endothelial cells to create a "super-adhesive" cell population for graft seeding.

### 6.3 Investigational Approaches

- **Monoclonal Antibodies:** Antibodies targeting the extracellular domain of FLRT2 could be used to modulate its adhesive functions. For example, blocking FLRT2-FGFR1 interaction might enhance FGF signaling in contexts where this is desirable (e.g., tissue repair).
- **Peptide Mimetics:** Small peptides mimicking the LRR domain of FLRT2 could be used to disrupt FLRT2-mediated cell adhesion in pathological conditions.
- **Gene Therapy:** For diseases caused by FLRT2 loss-of-function, adeno-associated virus (AAV) vectors carrying the FLRT2 cDNA could restore expression. This approach is theoretically applicable to congenital heart defects or neurodegenerative conditions.

### 6.4 Pharmacogenomic Considerations

The response to demethylating agents may vary based on the methylation status of the FLRT2 promoter. Patients with highly methylated FLRT2 promoters may benefit more from DNMT inhibitor therapy. Therefore, assessing FLRT2 promoter methylation status could serve as a predictive biomarker for treatment response.

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for FLRT2 research.

| Database | Accession / ID | Description |
| :--- | :--- | :--- |
| **NCBI Gene** | 23768 | Gene-specific information, genomic context, and links to literature. |
| **Ensembl** | ENSG00000156475 | Genome annotation, transcripts, and variation data. |
| **UniProt** | O43155 | Protein sequence, functional annotations, and post-translational modifications. |
| **RCSB PDB** | N/A (Homology models) | Structural data; use AlphaFold/UniProt for predicted structures. |
| **OMIM** | 604805 | Mendelian inheritance and phenotype links. |
| **ClinVar** | Gene: FLRT2 | Human variations and their clinical significance. |
| **STRING** | 9606.ENSP00000286698 | Protein-protein interaction networks. |
| **BioGRID** | 120596 | Physical and genetic interactions. |
| **Gene Ontology (GO)** | GO:0007155 (cell adhesion), GO:0005102 (signaling receptor binding), GO:0005886 (plasma membrane) | Functional annotations. |
| **The Cancer Genome Atlas (TCGA)** | FLRT2 | Expression and methylation data across cancer types. |
| **GEO** | Various | Microarray and RNA-seq datasets. |

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)

## References

[1] Yang, S., Huang, L., Liang, H., Guo, J., Liu, L., Chen, S., & Cao, M. (2023). Loss of flrt2 gene leads to microphthalmia in zebrafish. *Biology Open*. https://www.semanticscholar.org/paper/1551f07df3b3cc18732a70dc94dac25e5455c003

[2] Tao, Y., Yu, X., Cong, H., Li, J., Zhu, J., Ding, H., Chen, Q., & Cai, T. (2024). Identification of FLRT2 as a key prognostic gene through a comprehensive analysis of TMB and IRGPs in BLCA patients. *Frontiers in Oncology*. https://www.semanticscholar.org/paper/7feb003c62dd57275405a5b0b381cbed5f188026

[3] Guo, X., Song, C., Fang, L., Li, M., Yue, L., & Sun, Q. (2020). FLRT2 functions as Tumor Suppressor gene inactivated by promoter methylation in Colorectal Cancer. *Journal of Cancer*. https://www.semanticscholar.org/paper/0cfae3dc46fd6403e64e3f70163c56fdf46d192c

[4] Rao, S., & Tefft, B. J. (2025). FLRT2 silencing enhances endothelial cell retention on synthetic vascular graft materials under fluid shear stress in vitro. *Arteriosclerosis, Thrombosis and Vascular Biology*. https://www.semanticscholar.org/paper/213999b17f686214464eeb31a1282f693f029c50

[5] Rao, S., Wolfe, J., Chen, Y., & Tefft, B. J. (2024). Endothelial Cells With Silenced Flrt2 Expression Exhibit Enhanced Retention On Vascular Graft Materials Under Fluid Shear Stress In Vitro. *Arteriosclerosis, Thrombosis and Vascular Biology*. https://www.semanticscholar.org/paper/8c90888e0d36d2010938432f5a37d1e66dfead3d

[6] Jiang, P., Ning, J., Yu, W., Rao, T., Ruan, Y., & Cheng, F. (2023). FLRT2 suppresses bladder cancer progression through inducing ferroptosis. *Journal of Cellular and Molecular Medicine*. https://www.semanticscholar.org/paper/155e2cadf6be247874f9978e1982da1d0431d55a

[7] Bae, H., Kim, B., Lee, H., Lee, S., Kang, H., & Kim, S. (2017). Epigenetically regulated Fibronectin leucine rich transmembrane protein 2 (FLRT2) shows tumor suppressor activity in breast cancer cells. *Scientific Reports*. https://www.semanticscholar.org/paper/3008e45fe04279c79e9dbad4fcf16f956dfa5efe

[8] Tang, Z., Qian, Y., Wang, N., Chen, Y., Huang, H., Zhang, J., Luo, H., Lu, Z., Li, Z., He, Z., & Tang, F. (2025). HPV-Associated Gene Signatures in Bladder Cancer: A Comprehensive Prognostic Model and its Implications in Immunotherapy. *International Journal of Medical Sciences*. https://www.semanticscholar.org/paper/10ec50eb6555e9f40a6a47da3814963ec880a5f2

[9] Chung, K. (2009). Gene expression analysis of Flrt1, Flrt2 and Flrt3 in the murine midface during early embryogenesis. *Scientific Publication*. https://www.semanticscholar.org/paper/137f8bb0f4882eefc4a4807b79f971a74f80f118

[10] Müller, P., Schulz, R., Maretto, S., Costello, I., Srinivas, S., Bikoff, E., & Robertson, E. (2011). The fibronectin leucine-rich repeat transmembrane protein Flrt2 is required in the epicardium to promote heart morphogenesis. *Development*. https://www.semanticscholar.org/paper/b2f7fe8fd48afd7b01e2b4b13a485206232a58b5

[11] Hernández-Montiel, W., Cob-Calan, N. N., Cahuich-Tzuc, L. E., Rueda, J., Quiroz-Valiente, J., Meza‐Villalvazo, V., Zamora-Bustillos, R. (2022). Runs of Homozygosity and Gene Identification in Pelibuey Sheep Using Genomic Data. *Diversity*. https://www.semanticscholar.org/paper/f50a7f9dfc976be063f19ae4f64add059ee61095

[12] Lacy, S. E., Bönnemann, C., Buzney, E., & Kunkel, L. M. (1999). Identification of FLRT1, FLRT2, and FLRT3: a novel family of transmembrane leucine-rich repeat proteins. *Genomics*. https://www.semanticscholar.org/paper/f209b766a851a24afc97bc68c138d6fb9cda8984

[13] Gong, S., Mai, S., Chung, K., & Wei, K. (2009). Flrt2 and Flrt3 have overlapping and non-overlapping expression during craniofacial development. *Gene Expression Patterns*. https://www.semanticscholar.org/paper/f5f17e95c12d56f0ceb9d70ad72593b6a5efc597

[14] Dds, A., & Zollanvari, A. (2021). Modulating Cancer Progression from Leukoplakia via Bayesian Gene Networks. *Scientific Publication*. https://www.semanticscholar.org/paper/5430facfb1c587da63290cd0a417d6040c246dd7

[15] Rakheja, I., Panda, G., Maiti, S., & Ray, A. (2025). Molecular Modeling of Non-Canonical Intramolecular RNA Triple Helix Structures Predicted from TRIPinRNA and Their In Vitro Biophysical Structure Validation. *Journal of Physical Chemistry B*. https://www.semanticscholar.org/paper/79f0de55eeae532d9bbb7bd060d919208ba924c5

[16] Li, M., Sun, Y., Zhang, L., Lu, Z., Wo, H., Shao, F., Tang, S., Zhao, Y., Dai, J., & Yi, H. (2026). ITPG: an immune-related transcriptomic predictive model for gastric cancer prognosis. *Translational Cancer Research*. https://www.semanticscholar.org/paper/e631cb7d2cf1e9f51c24b4cca9003389c41630b1

[17] Lin, S., Tsai, C., Lee, Y., Chu, S., & Chen, N. (2014). Gene expression profiles in peripheral blood mononuclear cells of asian obstructive sleep apnea patients. *Biomedical Journal*. https://www.semanticscholar.org/paper/8c5e27e072a9716dca17a05b885a08f0b91e9259

[18] Kusakabe, M., Kutomi, T., Watanabe, K., Emoto, N., Aki, N., Kage, H., Hamano, E., Kitagawa, H., Nagase, T., Sano, A., Yoshida, Y., Fukami, T., Murakawa, T., Nakajima, J., Takamoto, S., Ota, S., Fukayama, M., Yatomi, Y., Ohishi, N., & Takai, D. (2010). Identification of G0S2 as a gene frequently methylated in squamous lung cancer by combination of in silico and experimental approaches. *International Journal of Cancer*. https://www.semanticscholar.org/paper/6dd486fc1e51ab9f457e9a634ae1c8006e04fc68

[19] Mostafa, M., Rider, C. F., Shah, S. V., Traves, S., Gordon, P. M. K., Miller‐Larsson, A., Leigh, R., & Newton, R. (2019). Glucocorticoid-driven transcriptomes in human airway epithelial cells: commonalities, differences and functional insight from cell lines and primary cells. *BMC Medical Genomics*. https://www.semanticscholar.org/paper/3b317db416257bab454fbdc6e0eac9b48a2ed93d

[20] Nation, J. B., Cabot-Miller, J., Segal, O., Lucito, R., & Adaricheva, K. (2021). Combining Algorithms to Find Signatures That Predict Risk in Early-Stage Stomach Cancer. *J. Comput. Biol.*. https://www.semanticscholar.org/paper/5eb9ff3cb0ab197d32b6121641c576aa95ede79e

[21] Chen, F., Chen, J., Wang, H., Tang, H., Huang, L., Wang, S., Wang, X., Fang, X., Liu, J., Li, L., Ouyang, K., & Han, Z. (2021). Histone Lysine Methyltransferase SETD2 Regulates Coronary Vascular Development in Embryonic Mouse Hearts. *Frontiers in Cell and Developmental Biology*. https://www.semanticscholar.org/paper/ea8295c9d9c85b755f2996e93b2f1fa432851707

[22] Kechin, A., Borobova, V., Kel, A., Ivanov, A. P., & Filipenko, M. (2022). ErbB4 Is a Potential Key Regulator of the Pathways Activated by NTRK-Fusions in Thyroid Cancer. *Applied Sciences*. https://www.semanticscholar.org/paper/de07a89740b5fb88c13d2f260829b29c741b2b43

[23] He, P., Sun, L., Zhu, D., Zhang, H., Zhang, L., Guo, Y., Liu, S., Zhou, J., Xu, X., & Xie, P. (2016). Knock-Down of Endogenous Bornavirus-Like Nucleoprotein 1 Inhibits Cell Growth and Induces Apoptosis in Human Oligodendroglia Cells. *International Journal of Molecular Sciences*. https://www.semanticscholar.org/paper/1d70d3f8e871956ef301f88a96b11d04bfffd99e

[24] Mosakhani, N., Pazzaglia, L., Benassi, M., Borze, I., Quattrini, I., Picci, P., & Knuutila, S. (2013). MicroRNA expression profiles in metastatic and non-metastatic giant cell tumor of bone. *Histology and Histopathology*. https://www.semanticscholar.org/paper/d585d5c382d54f76cbd301093db46bcedaadef8c

[25] Mamoor, S. (2021). Differential expression of fibronectin leucine rich transmembrane protein 2 in cancers of the breast. *Scientific Publication*. https://www.semanticscholar.org/paper/97ab569578eeb29160a11acf77c2daa2baee8d98

[26] Bernerd, F., Duval, C., Lacharriere, O. D., Nouveau, S., & Marat, X. (2012). Signature moléculaire des taches pigmentaires cutanées, associée à l'organisation de la matrice extracellulaire. *Scientific Publication*. https://www.semanticscholar.org/paper/c964e905753cf75fa8afcd61a39a740c0edf03be

[27] Fleitas, C., Marfull-Oromí, P., Chauhan, D., del Toro, D., Peguera, B., Zammou, B., Rocandio, D., Klein, R., Espinet, C., & Egea, J. (2021). FLRT2 and FLRT3 Cooperate in Maintaining the Tangential Migratory Streams of Cortical Interneurons during Development. *Journal of Neuroscience*. https://www.semanticscholar.org/paper/f07ed0b11a2a3f37a761dc9ed181872c79a6365e

[28] Boitard, S., Paris, C., Sevane, N., Servin, B., Bazi-Kabbaj, K., & Dunner, S. (2021). Gene Banks as Reservoirs to Detect Recent Selection: The Example of the Asturiana de los Valles Bovine Breed. *Frontiers in Genetics*. https://www.semanticscholar.org/paper/fae525b2e2967899ff05898c2e9dd11a370b516c

[29] Wang, Q., Fang, C., Xue, L., Wang, X., Zhai, C., Zhao, Y., Xiao, Q., Wang, T., & Xiong, L. (2025). Molecular insights into neurodevelopmental abnormalities and rescue mechanisms in the fetal prefrontal cortex with tetralogy of Fallot. *Discover Neuroscience*. https://www.semanticscholar.org/paper/53c2e26b4fc8a8ce812a9113aa3f30831b867f2c

[30] de Matos, F. M. S. A. (2009). Análise dos genes Flrt2 e Flrt3 no desenvolvimento da barbatana peitoral em peixe-zebra. *Scientific Publication*. https://www.semanticscholar.org/paper/e8f7610c7757d2281147bbadfba44b816d276e34

[31] Mayoral-Peña, K., Peña, O. I. G., Artzi, N., & Donato, M. (2025). Biomarker discovery for early breast cancer diagnosis using machine learning on transcriptomic data for biosensor development. *Comput. Biol. Medicine*. https://www.semanticscholar.org/paper/6924a9ec12e8cd1291ff62b782558abf9c0490d6

[32] Lei, L., Yao, D., Huang, J., Wei, J., & Mo, B. (2026). Identification of